Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development
March 16 2017 - 7:00AM
Business Wire
Biogen (NASDAQ:BIIB) today announced the appointment of
Anirvan Ghosh, Ph.D., as senior vice president, Research and Early
Development (RED). Dr. Ghosh will lead Biogen’s RED organization in
the discovery and development of drug candidates from idea through
proof of concept. He will report to Michael Ehlers, M.D., Ph.D.,
executive vice president, Head of Research and Development. Dr.
Ghosh will begin his service at Biogen in April.
“We are excited to have Anirvan Ghosh join us at Biogen,” said
Dr. Ehlers. “After an extensive global search, we have found an
inspired leader to guide an exceptional Research and Early
Development team. Anirvan is an accomplished neuroscientist and
industry R&D leader who has delivered multiple novel drug
candidates to the clinic.”
Dr. Ghosh joins Biogen from E-Scape Bio, where he served as
chief scientific officer. Prior to heading discovery efforts for
Alzheimer’s disease and neurodegenerative disorders at E-Scape Bio,
he served as vice president, Global Head of Neuroscience Discovery
and Biomarkers at Roche. In this capacity, Dr. Ghosh led research
and drug discovery for programs addressing neurodegenerative
diseases as well as neurodevelopmental and psychiatric
disorders.
“Biogen has been a pioneer in bringing breakthrough medicines to
patients with multiple sclerosis and spinal muscular atrophy, as
well as finding new approaches for Alzheimer’s disease, Parkinson’s
disease, and ALS – conditions that represent some of the hardest
challenges in medicine,” said Dr. Ghosh. “I am excited and honored
to lead Research and Early Development, and I look forward to
accelerating our efforts to translate the highest quality science
and our best ideas into a new generation of medicines at
Biogen.”
Prior to joining industry, Dr. Ghosh served as a professor on
the neuroscience faculties of the Johns Hopkins University and the
University of California, San Diego. His academic research has
focused on understanding how connections in the brain are
established during development and how these connections may be
affected in neurodevelopmental disorders. Dr. Ghosh received a BS
in Physics from the California Institute of Technology, a Ph.D. in
Neuroscience from Stanford University, and postdoctoral training at
Harvard Medical School. He is the author of more than 90 scientific
publications.
About Biogen
Through cutting-edge science and medicine, Biogen discovers,
develops and delivers worldwide innovative therapies for people
living with serious neurological and neurodegenerative diseases.
Founded in 1978, Biogen is a pioneer in biotechnology and today the
Company has the leading portfolio of medicines to treat multiple
sclerosis, has introduced the first and only approved treatment for
spinal muscular atrophy, and is at the forefront of neurology
research for conditions including Alzheimer’s disease, Parkinson’s
disease and amyotrophic lateral sclerosis. Biogen also manufactures
and commercializes biosimilars of advanced biologics. For more
information, please visit www.biogen.com. Follow us on social media
– Twitter, LinkedIn, Facebook, YouTube.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170316005510/en/
BiogenMark Dole, +1
781-464-3260public.affairs@biogen.comorBenjamin Strain, +1
781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024